@cytel profile picture
Cytel Inc. @cytel

Shaping the future of drug development with software solutions, innovative consulting and proven clinical research services.

Joined October 2012
  • Tweets 5,584
  • Following 619
  • Followers 1,089
3,149 Photos and videos
DMCs play a crucial role in maintaining the integrity of clinical trials, offering independent oversight to balance the potential benefits of new therapies against risks. David Kerr, an expert with over 30 years of experience, offers his insights: hubs.ly/Q04l9xNt0
16
SDTM is standardized. Implementations are not! We discuss how, by analyzing metadata at scale, we can see patterns that are invisible in a single study, and how metadata may be one of the best tools we have to bring standards back into alignment. hubs.ly/Q04l0GR50
8
Biometrics teams are under pressure to reduce timelines, control costs & ensure data quality. AI is emerging as a powerful enabler in achieving these goals—transforming how data is managed, analyzed & interpreted across clinical programs. Watch on-demand: hubs.ly/Q04kBPyz0
6
Cytel will be at the BIO International Convention in San Diego! 📍 Stop by Booth #5857 to speak with our experts! Don't miss: 👉 "Business Development Fundamentals" Wyatt Gotbetter June 19th at 8:30 AM Book a meeting: hubs.ly/Q04kLpRh0 See you in San Diego! 👋
20
The gold standard for randomized clinical study design is the double-blind, but this is not always possible. We discuss randomized open-label studies and best practices to minimize potential bias. hubs.ly/Q04kywXY0
6
Organizations are moving beyond static submissions toward more dynamic & continuously updated evidence packages. As agencies explore the role of AI, adoption brings important questions. We will explore how AI is reshaping HTA, offering practical insights: hubs.ly/Q04jpvdb0
6
BICR enhances the objectivity & regulatory credibility of oncology trial endpoints by minimizing bias & standardizing radiographic assessments. But, as we discuss, its implementation introduces some key challenges: hubs.ly/Q04krsXp0 #oncology #cancer #BICR #clinicaltrials
20
Significant barriers continue to slow progress in closing the women’s health gap, despite growing awareness and guidance from the FDA. Join us for a panel exploring how this requires a structural transformation across biostatistics and data management: hubs.ly/Q04jrLsH0
8
Curious to know more about how R Shiny can strengthen evidence communication across the HTA process? Join us for an Office Hours session on how to utilize R Shiny to enhance payer engagement, internal alignment, and post-submission value communication: bit.ly/4vvpmrP
11
Clinical Operations teams are being asked to let go of traditional approaches & do more than ever before. We discuss how to meet these challenges with methods & tools that allow you to spend less time managing the process & more time managing the study. bit.ly/4dWmKfl
18
ISPOR Philadelphia showed an industry moving rapidly from AI experimentation toward AI-enabled infrastructure. Manuel Cossio and Dalia Dawoud share some of their key takeaways and insights on the rise of AI and what will define the next phase of HEOR. hubs.ly/Q04j76nw0
18
Curious to know more about how R Shiny can strengthen evidence communication across the HTA process? Join us for an Office Hours session on how to utilize R Shiny to enhance payer engagement, internal alignment, and post-submission value communication: hubs.ly/Q04j34J30
17
In clinical development, the demand for faster, more accurate, and scalable solutions around patient data is increasing rapidly. We discuss how AI and automation are reshaping statistical programming, and how to adopt these tools responsibly. hubs.ly/Q04gTf-60
14
Organizations are moving beyond static submissions toward more dynamic & continuously updated evidence packages. As agencies explore the role of AI, adoption brings important questions. We will explore how AI is reshaping HTA, offering practical insights: hubs.ly/Q04hMFDs0
10
Curious to know more about how R Shiny can strengthen evidence communication across the HTA process? Join us for an Office Hours session on how to utilize R Shiny to enhance payer engagement, internal alignment, and post-submission value communication: hubs.ly/Q04hs23C0
14
Even the strongest trial designs can face challenges once execution begins. Join us for an informal Office Hours session, where you can bring your questions directly to our experts across trial design and execution: hubs.ly/Q04hcYR60
10
Database Lock is a critical milestone in the clinical trial lifecycle. A final step of clinical data management, DBL can sometimes require accelerated timelines. Veronica Chan discusses how to achieve DBL on time and without sacrificing data quality: hubs.ly/Q04gSQYg0
24
Cytel will be at ISPOR US in Philadelphia! 📍 Visit us at booth #1039 to speak with our experts in HEOR, Market Access, and RWE and learn more about our innovative offerings. We hope to see you there! Book a meeting: hubs.ly/Q04gynRj0
20
Researchers are exploring ways to generate “synthetic” patient cohorts that behave like real ones. Manuel Cossio and Deepa Jahagirdar discuss a pilot study that explores how LLMs can play a meaningful role in this transformation: hubs.ly/Q04gDymh0
19
Cytel will be at the CDISC TMF EU Interchange in Milan! Angelo Tinazzi shares a preview of upcoming presentations on Cytel’s work with CDISC standards, including datasets JSON and CORE. hubs.ly/Q04g8KMh0 We hope to see you there!
2
45
Load more